Pulse Biosciences (NASDAQ:PLSE) Hits New 12-Month High - What's Next?

Key Points

• Pulse Biosciences shares reached a new 52-week high, trading as high as $34.00 and last changing hands near $33.74, up from a prior close of $32.79.
• Analyst sentiment is generally positive, with three Buy ratings and one Sell rating producing a consensus “Moderate Buy” rating and an average price target of $32.33.
• Recent quarterly results exceeded expectations, while significant insider ownership and purchases—including a nearly $13 million buy by director Robert W. Duggan—provided additional investor interest.

Pulse Biosciences, Inc (NASDAQ:PLSE - Get Free Report)'s share price hit a new 52-week high during mid-day trading on Tuesday . The stock traded as high as $34.00 and last traded at $33.7360, with a volume of 16031 shares changing hands. The stock had previously closed at $32.79.

Analysts Set New Price Targets

Several equities research analysts recently commented on PLSE shares. Weiss Ratings reissued a "sell (d-)" rating on shares of Pulse Biosciences in a research note on Friday, July 17th. Oppenheimer reiterated an "outperform" rating on shares of Pulse Biosciences in a research note on Tuesday. Finally, Canaccord Genuity Group began coverage on shares of Pulse Biosciences in a research report on Thursday, June 4th. They issued a "buy" rating and a $32.00 target price for the company. Three analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $32.33.

Pulse Biosciences Stock Performance

The company has a 50-day simple moving average of $26.90 and a 200 day simple moving average of $22.27. The company has a market capitalization of $2.32 billion, a P/E ratio of -30.37 and a beta of 1.65.

Pulse Biosciences (NASDAQ:PLSE - Get Free Report) last posted its quarterly earnings data on Monday, May 4th. The company reported ($0.27) earnings per share for the quarter, beating the consensus estimate of ($0.32) by $0.05. The business had revenue of $0.40 million during the quarter, compared to the consensus estimate of $0.25 million. As a group, sell-side analysts forecast that Pulse Biosciences, Inc will post -1.29 earnings per share for the current year.

Insider Buying and Selling at Pulse Biosciences

In related news, Director Robert W. Duggan bought 660,233 shares of the business's stock in a transaction that occurred on Monday, May 11th. The stock was purchased at an average cost of $19.69 per share, for a total transaction of $12,999,987.77. Following the purchase, the director directly owned 48,211,433 shares in the company, valued at $949,283,115.77. This trade represents a 1.39% increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Paul A. Laviolette bought 15,000 shares of Pulse Biosciences stock in a transaction that occurred on Monday, May 11th. The stock was bought at an average price of $19.69 per share, with a total value of $295,350.00. Following the purchase, the chief executive officer owned 15,000 shares of the company's stock, valued at $295,350. This trade represents a ∞ increase in their position. The SEC filing for this purchase provides additional information. 74.00% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Pulse Biosciences

A number of institutional investors have recently bought and sold shares of PLSE. BNP Paribas Financial Markets raised its stake in shares of Pulse Biosciences by 63.6% in the 2nd quarter. BNP Paribas Financial Markets now owns 1,749 shares of the company's stock valued at $26,000 after buying an additional 680 shares in the last quarter. Tower Research Capital LLC TRC boosted its position in shares of Pulse Biosciences by 275.0% during the 2nd quarter. Tower Research Capital LLC TRC now owns 2,940 shares of the company's stock valued at $44,000 after acquiring an additional 2,156 shares in the last quarter. Russell Investments Group Ltd. increased its stake in Pulse Biosciences by 13.8% in the fourth quarter. Russell Investments Group Ltd. now owns 5,106 shares of the company's stock valued at $70,000 after acquiring an additional 619 shares during the period. The Manufacturers Life Insurance Company bought a new stake in Pulse Biosciences in the second quarter valued at about $158,000. Finally, Brevan Howard Capital Management LP acquired a new position in Pulse Biosciences in the second quarter worth about $215,000. Institutional investors and hedge funds own 76.95% of the company's stock.

About Pulse Biosciences

Pulse Biosciences, Inc is a clinical-stage bioelectric medicine company that develops and commercializes medical devices based on its proprietary Tissue NanoPoration (TNP) platform. The company’s core technology, NanoPulse Stimulation (NPS), delivers ultrashort, high-voltage electric pulses to targeted tissue, triggering cellular responses without the thermal damage associated with traditional energy-based devices. Pulse Biosciences focuses on applications in dermatology and aesthetic medicine, where controlled ablation of unwanted lesions is critical.

The company’s flagship product, the CellFX® System, is designed to treat a range of benign and malignant skin lesions, including seborrheic keratosis, non-melanoma skin cancers, and various epidermal and dermal lesions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.